PCK2 and cancer: As pointed out in a previous study that PEPCK‐mediated metabolic remodeling contributes to histone methylation, which regulates cancer progression,[14] we first pointed out that IGF2BP3lac mediated PCK2 upregulation promotes the whole levels of m6A‐modification and the anti‐TKI drug phenotype.